Can I read Osimertinib in Combination With Bevacizumab For EGFR Mutated Recurrent Glioblastoma GBM A Case Report on EtoBox?

Osimertinib in Combination With Bevacizumab For EGFR Mutated Recurrent Glioblastoma GBM A Case Report by Athenaeum Scientific Publishers is a document available to read on EtoBox.

What is Osimertinib in Combination With Bevacizumab For EGFR Mutated Recurrent Glioblastoma GBM A Case Report about?

Glioblastoma is the most common primary, malignant adult brain tumor with a median overall survival of 12-15 months after diagnosis. The standard of care includes maximal safe resection, chemoradiation, adjuvant chemotherapy with the DNA alkylator, temozolomide and tumor-treating fields. Given the recent advances in targeted molecular therapeutics and tissue sequencing, there is a growing opportunity for precision medicine in GBM treatment. In this case report, we present two patients who were f

Author

Athenaeum Scientific Publishers

Language

EN